This is the results of the clinical trial of CED delivery of carboplatin for the treatment of recurrent high grade gliomas. It is based on data from a grant we gave for a rat trial (see previous article). This was funded by our friends at Voices Against Brain Cancer. Overall the results are not impressive. The dose was way too low but the FDA required they start so low and slowly increase it. They started at 1 ug, then upped it to 2ug, then ended with 4ug, and did not get significant side effects. In the rat study, they found the best dosage for rats was 72ug and rats are way smaller than people. So I would like to see this repeated but with reasonable doses.